Press Releases

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

Aug 25, 2026

Read More

BioCryst Reports Second Quarter 2026 Financial Results

Aug 05, 2026

Read More

BioCryst to Report Second Quarter 2026 Financial Results on August 5

Jul 22, 2026

Read More

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Jul 15, 2026

Read More

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 02, 2026

Read More

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Jun 29, 2026

Read More

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

Jun 12, 2026

Read More

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 09, 2026

Read More

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

May 27, 2026

Read More

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

May 13, 2026

Read More